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Summary We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas.
This oncogene, named PTC, is a novel rearranged version of the ret proto-oncogene. In fact PTC is the
product of the fusion of the tyrosine kinase domain of the ret proto-oncogene with the 5'-terminal region of
another gene that we have named H4. The ret proto-oncogene shows a pattern of expression restricted to
neuroendocrine tissue. Its fusion with H4 allows the expression of the activated form in thyroid papillary
carcinomas. Therefore the detection of ret transcripts is a tool to investigate ret activation in thyroid
neoplasms. Here we show the detection by in situ hybridisation, of activated ret transcripts in human thyroid
papillary neoplasms that were positive for PTC activation by Southern blot analysis. We did not find any ret
transcripts in papillary carcinomas negative for PTC activation, nor in normal thyroid and in non-papillary
thyroid neoplasias.
We have previously reported the activation of a novel
oncogene in about 20% of human thyroid papillary car-
cinomas and we have named this oncogene PTC (papillary
thyroid carcinoma) (Fusco et al., 1987; Grieco et al., 1990;
Bongarzone et al., 1989). PTC is a chimeric gene; in fact it is
the product of the fusion of the tyrosine-kinase encoding
domain of proto-ret (Takahashi et al., 1988) to the 5'-
terminal region of a still uncharacterised gene that we have
named H4 (Grieco et al., 1990). An inversion of the long arm
of chromosome 10 (invIOq ll.2-q21) is responsible for the
activation of PTC (Jenkins et al., 1990; Pierotti et al., 1992).
So far the activation of the ret oncogene has been found in
vivo only in thyroid carcinomas and it is restricted to papil-
lary histotype. The expression of the unrearranged ret proto-
oncogene in humans, is restricted to neuroendocrine tissues.
It has been reported, in fact, in pheochromocytomas medul-
lary thyroid carcinomas and neuroblastomas (Ikeda et al.,
1990; Santoro et al., 1990). Therefore the ret proto-oncogene
is not expressed in the thyroid follicular cells, while its
activated form (PTC) is expressed in the neoplastic cells
(Grieco et al., 1990). Thus the detection of its expression
might be considered as a valid tool to investigate ret activa-
tion in thyroid neoplasias.
Here we report the results obtained by in situ hybridisation
(ISH) as a technique able to detect in a single thyroid cell the
presence of ret transcripts.
Materials and methods
Tissues and cells
Five normal thyroids, seven adenomatous goiters and 15
thyroid carcinomas were obtained from human thyroidec-
tomy (Service de Chirurgie. Dr Peix, Dr Guibert. Hospices
Civils de Lyon, Lyon, France). The tumours were classified
as: papillary carcinomas (10 samples), follicular (three sam-
ples) and anaplastic carcinomas (two samples) according to
the International Histological Classification of Tumors
(Hedinger, 1988). The tissue fragments were frozen in liquid
nitrogen. Fragments of two papillary carcinomas were also
fixed by immersion in Bouin's solution for 24 h and embed-
ded in paraffin by already described methods. Human kidney
and rat liver tissues were used as negative controls. The rat
conceptus tissue expected to be a positive control (Szentir-
may et al., 1990) was obtained at day 11 of gestation.
The PTC transformed NIH 3T3 cells, that express high
levels of activated human ret oncogene (Grieco et al., 1990)
were injected subcutaneously into athymic mice (IFFA
CREDO, France) in order to obtain tumours used as positive
controls.
All the cells were cultivated in F12 medium supplemented
with 10% heat inactivated fetal bovine serum (Boerhinger
Mannheim).
Fixation andpreparation ofsection
6-8 1sm frozen fragments sections were obtained with a
cryocut (Reichert Yung, Wien, Austria) and placed on poly-
L-lysine coated slides. They were allowed to dry for 1 h at
room temperature (RT) before fixation in paraformaldehyde
(PAF) 4% in phosphate buffer saline (PBS) 0.1 M pH7.4, for
30 min at RT. Cultured cells were cytospun and fixed for
15 min in the same fixative. Bouin's fixed tissues were
deparafinised in toluene, dehydrated in a graded series of
ethanol before the treatment described above. All the speci-
mens were rinsed for 30 min three times in PBS. They were
treated by a proteinase K solution (1 tngml-' in 10 mM Tris-
HCL(pH8), 0.1 mM EDTA, prewarmed for 2 h at 37°C),
postfixed for 2 min in 4% PAF in PBS, washed for 5 min in
PBS, 5 min in sodium chloride 9% then dehydrated in
ethanol series (50°C, 70°C, 95°C, 100°C). They were stored at
- 20°C until use.
Hybridisation
Details of the technique are described elsewhere (Morrell,
1989). Briefly, the sections were incubated for 3 h at 37°C in
50% formamide, 5 SSC (20X:3M sodium chloride, 0.3 M
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sodium citrate pH7). After removing the prehybridisation
solution they were placed in a prewarmed solution made of:
50% formamide, 5 SSC, 1 x Denhardt's, 10% dextran sul-
fate, 0.05% Triton X100, 250 lag-' of yeast t-RNA,
250 ggml ' of salmon sperm DNA, 10 mM Dithiothreitol
(Sigma, France) and 0.5 ng tlml-' of 35S probe. The hyb-
ridisation was performed for 20 h at 42°C. The washings
were respectively: 4 SSC 50% formamide 1 h at RT, 2 SSC
1 h at RT, 2 SSC 1 h at 50°C, 1 SSC 1 h at RT, 0.5 SSC for
30 min at RT, 0.25 SSC for 1 h at RT.
Sections were dehydrated, air dried and exposed to Kodak
diagnostic films (X-OMAT, Kodak, NY, USA) for 48 h then
dipped in a NTB2 nuclear emulsion (Kodak) diluted 1:1
(vol/vol) with distilled water and exposed for 1-2 weeks at
4°C. The radioautographs were developed with Dektol for
3 min at 20°C (Kodak), fixed in 30% sodium thiosulfate for
6 min (Sigma), washed in distilled water and counterstained
with haematoxylin dye.
As a control the sections were pretreated with bovine
pancreatic RNase A (Boerhinger Mannheim) (100 Lgml-') in
2 x SSC for 30 min, or prehybridised with a saturating
amount of unlabelled probe (100-fold excess) before the hyb-
ridisation with the labelled one or hybridised with the sense
probe complimentary to the anti-sense probe or finally hyb-
ridised with no probe.
Synthetic oligodeoxynucleotides
The sequence of the synthesised oligodeoxynucleotide used as
probe is: 5'-CCAGATACTGCATCCCCTGTGAGATCTG-
CCAGGCAAATGAGATGAGGTCGC-3' (Laboratory of
molecular and cellular biology, ENS, Lyon, France). This
sequence corresponds to the 51 bp long antisense probe for
the tyrosine-kinase domain of the human ret proto-oncogene
(Szentirmay et al., 1990). The 51 bp long sense probe was
synthesised as well. The probes were purified by polyac-
rylamide gel electrophoresis and dissolved in 10 mM Tris,
0.1 mM EDTA at a concentration of 1 fgtI-'. They were
labelled at the 3 min terminus with 35S (9.25 MBq,
10mCiml-1, Amersham) using terminal dioxynucleotidyl
transferase (TdT, 50 U; Boerhinger Mannheim) according to
Lewis et al. (1986). The labelled probes were purified using a
G25 Sephadex quick spin column (Boerhinger Mannheim).
Results
To set up of the ISH technique for the ret proto-oncogene,
we used as a positive control an NIG/3T3 cell clone (Fusco
et al., 1987) (NIH3T3-PTC) and a rat thyroid epithelial cell
clone )PC-PTC) both transfected with the PTC oncogene
(Grieco et al., 1990; Santoro et al., 1990). As a probe to
detect ret expression we used a synthetic antisense oligodeox-
ynucleotide corresponding to its tyrosine kinase-encoding
domain. The specificity of this probe has been previously
reported (KD-probe: Szentirmay et al., 1990). Figure la
shows that NIH/3T3-PTC like PC-PTC (data not shown) cell
clones were homogeneously labelled, the latter containing
smaller amounts of activated ret transcripts. Also a tissue
section of a nude mouse tumour induced by NIH/3T3-PTC
cells gave a considerable strong signal (Figure lb). All the
cells were labelled. Conversely neither the normal untrans-
fected NIH/3T3 (Figure lc) nor the PC C13 cells (data not
shown) were positive.
As another positive control the placenta at day 11 of
gestation was examined and showed a strong signal among
the chorionic villus (data not shown). Some controls were
performed to confirm the specificity of the ISH technique:
pre-hybridisation of the section with a saturating amount of
the unlabelled probe resulted in a marked decrease in the
density of the grains; a RNAse pretreatment abolished nearly
completely the positive signal. Experiments of hybridisations
with the sense probe (Figure Id) or with the buffer free of
radiolabelled probe were negative. The optimal hybridisation
signal with the minimal background was obtained using str-
ingent washes with 0.25 SSC.
The tissue specificity was demonstrated by the negative
reactions obtained on the tissue of human kidney cells, both
cortical and medullary ones and on rat hepatocytes (data not
shown).
Thus we have analysed by the in situ mRNA hybridisation
15 human thyroid carcinomas, five specimens of normal
human thyroid tissue and seven adenomatous goiters. Among
the tumour samples 10 were of the papillary histotype, three
of the follicular and two of the anaplastic type. These thyroid
samples were previously analysed for the presence of an
activated form of the ret oncogene by Southern blot assay:
four of these ten papillary carcinomas displayed a rearrange-
ment of ret; all the other samples (six papillary, three folli-
cular and two anaplastic carcinomas) were negative (Santoro
et al., 1992). When we analysed these samples by ISH, we
found that the four papillary carcinomas harbouring an
activated ret scored positive. These sections showed numer-
ous grains patched on the thyrocytes (Figures 2a, b). The
distribution of the positive cells was observed along the
papillary trabeculae and the vesicles. The colloid, present in
the vesicles, and the fibroblasts were negative as an internal
negative tissue control (Figure 2a, b). Fixation of two of the
samples positive for PTC in Bouin's solution abolished
nearly completely the signal (not shown) suggesting that this
fixative must be avoided for mRNA detection analysis. Few
grains corresponding to the background were noted on the
thyrocytes of the five normal thyroids and of the seven
colloid adenoma goiters (Figure 2c). The 6 PTC negative
papillary tumours (Figure 2d), the three follicular and the
two anaplastic carcinomas also scored negative.
Discussion
Thyroid tumours consist of a wide spectrum of lesions, rang-
ing from benign colloid adenoma to malignant tumours such
as papillary, follicular, anaplastic and medullary carcinomas
(Williams, 1980; Hedinger, 1988). About 20% of human
thyroid papillary carcinomas harbour an activated form of
ret (Fusco et al., 1987; Bongarzone et al., 1989; Grieco et al.,
1990). The ret proto-oncogene is not expressed in normal
human thyrocytes, but only in neuroendocrine tissues (San-
toro et al., 1990; Ikeda et al., 1990). Its activation by the
fusion to the H4 promotor allows its expression in neoplastic
cells (Grieco et al., 1990). Thus we decided to use ISH as an
alternative tool to detect ret activation in thyroid tumours.
This activation can be demonstrated by the NIH/3T3 trans-
fection assay, Southern blot or Reverse PCR (RT-PCR) tech-
niques (Fusco et al., 1987; Bongarzone et al., 1989; Grieco et
al., 1990; Ishizaka et al., 1991). The transfection assay
requires a considerable amount of high molecular weight
DNA. The Southern blot is not very sensitive and can be
hampered by contamination of the tumour tissue with sur-
rounding normal cells. Finally the RT-PCR requires some
micrograms of intact RNA from the tumour lesion.
Therefore ISH can overcome these problems providing a
valid tool to detect ret activation. Moreover ISH has the
advantage to allow this analysis in single cells.
The setting up of the ISH technique was performed on
NIH/3T3-PTC and PC-PTC cells that expressed high levels
of activated human ret oncogene (Grieco et al., 1990; San-
toro et al., 1992) using as a probe a 51-mer oligonucleotide
corresponding to the kinase domain of the ret gene (Szentir-
may et al., 1990). We then analysed fifteen thyroid car-
cinomas. Only the four cases out of the ten papillary tumours
harbouring an activated ret scored positive for the presence
of ret transcripts. One out of the four cases showed a mixed
papillary-follicular structure. This finding supports the idea
that the classification of these types of thyroid carcinomas
sometimes as follicular should be reconsidered according to
the expression of ret. The other six papillary cases, three1096 N. FABIEN et al.
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Figure 1 ISH with a ret specific probe on NIH/3T3-PTC cells and on tumour induced by these latter cells in athymic mice.
Cytospined cultured cells and tissue cryostat section of the tumour were fixed in PAF and hybridised in a 50% formamide
containing buffer at 42°C with a 3' terminus 35S labelled oligonucleotide ret specific probe; the autoradiograms were exposed for 2
weeks (see Materials and methods). The cultured NIH/3T3-PTC cells and the sections of the tumour gave a strong hybridisation
signal (a and b respectively). Notice the great number of reduced silver grains over all the cells. No signal was observed on
untransfected NIH/3T3 (c). Few silver grains were dispersed on the tumour section hybridised with the sense labelled probe (d).
Magnifications: a-c x 1100; d x 800; bar = 10gim.
follicular and two anaplastic carcinomas were negative. Five
normal thyroid specimens and seven thyroid adenomas also
scored negative; therefore it is possible that the previously
reported low level expression of proto-ret in normal thyroid
(Santoro et al., 1990) could be ascribed to the parafollicular
thyroid C cells. In this study we did not observe positive
reaction on normal thyroid sections since these samples did
not arise from the portion of the thyroid where the C cells
are concentrated (Pont, 1979). Taking a sample of the
thyroid tissue at this precise localisation, we have been able
to demonstrate ret expression in C cells (manuscript in
preparation).
Preliminary data indicate that fusion with genes other than
H4 can activate ret in thyroid papillary carcinomas. It is
noteworthy that two of the papillary carcinomas positive for
ret expression in this study have been shown to carry an
H4/ret fusion, but in the other two cases the activation
occurred by fusion with a gene different from H4. Thus the
ISH is able to reveal different types of ret rearrangement all
leading to its inappropriate expression in thyroid follicular
cell.
We have observed that all the neoplastic cells of the four
ret positive papillary carcinomas displayed the presence of ret
transcripts: this suggests that ret activation is a clonal event
which is an important step in the generation of papillary
carcinomas. Recently Ishizaka et al. (1991) reported the
activation of ret in four of 19 follicular adenomas and in one
of two adenomatous goiter by an RT-PCR method (Ishizaka
et al., 1991). The activation was detected only in some
regions of the adenomas. The authors envisage either the
possibility that ret activation is not specific for the papillary
histotype or that these positive cases might reflect the
occurence of PTC activation only in a minor population of
cancerous or precancerous cells. There is in fact, a high
prevalence of thyroid microcarcinomas in the Japanese
population (Ishizaka et al., 1991). We suggest that the ISH
could solve this problem allowing a more precise analysis of
the cells positive for ret activation.
Finally the use of this analysis to investigate in situ car-
cinomas, microcarcinomas and fully developed thyroid car-
cinomas will contribute to clarify if the event of ret activation
is involved in the initiation or in the progression of this
neoplasia. In conclusion we demonstrate that ret activation
can be detected by ISH in PTC positive thyroid papillary
carcinomas which seem to be the most malignant tumour of
this histotype. Therefore ret activation, representing a specific
marker for this histotype, could be used to discriminate some
of the benign adenomas from the papillary thyroid car-
cinomas.DETECTION OF RET ONCOGENE ACTIVATION IN HUMAN PAPILLARY THYROID CARCINOMAS 1097
Figure 2 ISH of thyroid cryostat sections with a ret specific probe. The cryostat sections were fixed in PAF and hybnidised in a
50% formamide containing buffer at 42°C with a 3' terminus 35S labelled oligonucleotide ret specific probe; the autoradiograms
were exposed for 2 weeks (see Materials and methods). Positive hybridisation signal appeared only on the thyreocytes of the PTC
positive thyroid carcinoma (a and b). Many silver grains are found mainly in the cytoplasm while no grain are present over the
colloid (arrow). No transcripts were detected on the PTC negative papillary carcinomas (d) nor on colloid adenoma goiter (c).
Magnifications: a x 850; b-d x 300; bar =101im.
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